Arbeitsgruppe Hepatobiliäre Tumoren - Studien
| HCC - frühes Stadium |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0417/ass: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) (IMMULAB) | ||||
| --- in Rekrutierung --- | ||||
| HCC - intermediäres Stadium |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0217: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) (IMMUTACE) | ||||
| --- in Rekrutierung --- | ||||
| AIO-Studie | Für weitere Zentren offen |
zur Studie | ||
| AIO-HEP-0418: A randomized, 2-arm non-comparative phase II study on the effects of atezolizumab and Roche bevacizumab (atezo/bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and atezo/bev on 24-Months survival rate in the treatment of BCLC B hepatocellular carcinoma patients. (DEMAND) |
||||
| --- in Planung, Studienstart Q3 2019 --- | ||||
| HCC - fortgeschrittenes Stadium |
| AIO-assoziierte Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0318/ass: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations | ||||
| --- in Rekrutierung--- | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0218/ass: An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) [IMMUNIB] | ||||
| --- in Rekrutierung --- | ||||
| Biliäre Tumoren - adjuvant |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0112: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial | ||||
| ---in Rekrutierung--- | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0118/ass: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR) – The AIO/ CALGP/ ACO- GAIN-Trial - |
||||
| ---in Vorbereitung, Studienstart in Q2 2019 geplant, weitere Zentren sind sehr erwünscht! --- | ||||
| Biliäre Tumoren - first line |
| AIO-assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-HEP-0119/ass: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care [IMMUWHY] | ||||
| --- in Vorbereitung, FPI Q2/2019 geplant --- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0117: A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma [IMMUCHEC] | ||||
| --- in Rekrutierung --- | ||||
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-YMO/HEP-0315: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial (NIFE) | ||||
| ---in Rekrutierung--- | ||||
| Biliäre Tumoren - second line |
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.drks.de | zur Studie | ||
| AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL) | ||||
| ---in Rekrutierung--- | ||||
| Registerstudien |
| AIO-Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-HEP-0219/ass: Platform for Analyzing Targetable Tumor Mutations - PLATON | ||||
| --- in Vorbereitung – Studienstart noch offen, FPI Q4 2019 geplant --- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 15.07.2019 |